GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 59.31B |
| Revenue (ttm) | 31.63B |
| Net Income (ttm) | 3.42B |
| Shares Out | 4.03B |
| EPS (ttm) | 0.83 |
| PE Ratio | 17.83 |
| Forward PE | 8.59 |
| Dividend | 0.61 (4.17%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 7,032,406 |
| Average Volume | 7,310,542 |
| Open | 1,464.00 |
| Previous Close | 1,463.00 |
| Day's Range | 1,460.00 - 1,479.00 |
| 52-Week Range | 1,242.50 - 1,649.25 |
| Beta | 0.29 |
| RSI | 53.00 |
| Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK Commits $30B to Boost U.S. Pharma Expansion
GSK Commits $30B to Boost U.S. Pharma Expansion
GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years
GSK plc (NYSE: GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years . The update inclu...
GSK Just Dropped $30 Billion on America's Biotech Future--Here's What That Buys
GSK Just Dropped $30 Billion on America's Biotech Future--Here's What That Buys
GSK to Invest $30 Billion in U.S. R&D and Supply Chain Infrastructure
GSK to Invest $30 Billion in U.S. R&D and Supply Chain Infrastructure
GSK Unveils U.S. Expansion Plans to Counter Tariff Threats
GSK Unveils U.S. Expansion Plans to Counter Tariff Threats
GSK to Invest $30B in U.S. R&D and Infrastructure
GSK to Invest $30B in U.S. R&D and Infrastructure
GSK unveils $30B U.S. investment after Trump arrives in U.K. for state visit
GSK pledges $30bn US investment as UK's pharma woes deepen
The company is the latest pharma firm to have either reduced spending in the UK or diverted it to the US.
GSK to invest $30 billion in US over 5 years, unveils $1.2 billion biologics project in Pennsylvania
Pharmaceutical major GSK plc has announced plans to invest $30 billion in the United States over the next five years, including a new $1.2 billion project focused on manufacturing, artificial intellig...
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
FTSE 100 Live 17 September: Inflation update, GSK unveils $30bn US investment
The UK’s annual rate of inflation has stayed at the highest level since January 2024.
GSK Plans To Invest $30 Bln In R&D And Manufacturing In US Over Next 5 Years
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Wednesday its plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the ne...
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
GSK plans $30 billion US investment as pharma tariff threat looms
GSK said on Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the United States over the next five years, after U.S. President Donald Trump arrive...
GSK Says It Will Spend $30B on U.S. Manufacturing and R&D
The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.
NHS must reverse decline in drugs investment, says science minister
Patrick Vallance says UK must improve relations with pharmaceuticals industry as firms scrap plans The UK is “determined to solve” its standoff with the pharmaceutical industry and reverse a 10-year d...
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.
Dividend Income Summary: Lanny's July 2025 Summary
In July, we (my wife and I) received a dividend income total of $4,161.64. My other two Vanguard ETFs – S&P 500 (VOO) and Dividend Appreciation ETF (VIG) - both paid in July. We had a solid increase m...
Recent Report Shows That Rep. Robert Aderholt Sold Up to $15K Worth of GSK Stock
Records from September 10, 2025 indicate that Representative Robert Aderholt of Alabama made a sale of GSK (NYSE: GSK), valued between $1,001 and $15,000, with the transaction dated July 28, 2025 and...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Hong Kong to launch collaborative study on long-term effects of shingles vaccine
A Hong Kong government-owned clinical trial institute will launch a study to examine the long-term health effects of the shingles vaccine in real-world settings, collaborating with a global pharmaceut...
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences Ltd . (NASDAQ: WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency...
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.
What's Driving the Market Sentiment Around GSK?
GSK's (NYSE: GSK) short percent of float has fallen 9.68% since its last report. The company recently reported that it has 11.29 million shares sold short , which is 0.56% of all regular shares that ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK).